NCT04457596 2025-10-29T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialAlliance for Clinical Trials in OncologyPhase 3 Active not recruiting1,056 enrolled